| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698729 | Clinical Oncology | 2014 | 7 Pages |
Abstract
Panitumumab monotherapy seems to be a safe and active second-line treatment for patients with wild-type KRAS mCRC, with activity in line with that seen for irinotecan monotherapy, but with less toxicity. CEA may provide a useful early indicator of response to panitumumab.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
I.E.G. van Hellemond, G.J. Creemers, L.J.C. van Warmerdam, F.A. de Jong, R.H.T. Koornstra,